InnoCan Pharma Corporation
INNO
CNSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -67.01% | 1,850.00% | -571.38% | -275.07% | 67.06% |
| Total Depreciation and Amortization | -20.00% | 100.00% | 22.22% | -10.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -51.36% | -356.88% | 140.43% | 5,007.69% | -35.33% |
| Change in Net Operating Assets | -47.83% | 167.40% | 90.44% | 91.43% | 105.64% |
| Cash from Operations | -237.50% | -15.28% | 102.19% | 1.63% | 149.26% |
| Capital Expenditure | -- | -50.00% | 33.33% | 66.67% | -150.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -98.55% | -- | -- | -- |
| Cash from Investing | -- | -107.69% | 33.33% | 33.33% | -100.00% |
| Total Debt Issued | -29.69% | -- | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | 50.00% | 20.00% | 20.00% |
| Issuance of Common Stock | -- | -- | -100.00% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -100.00% | -100.00% | -- | -56.94% |
| Cash from Financing | -54.82% | -100.00% | -100.35% | 3,160.00% | -31.31% |
| Foreign Exchange rate Adjustments | -33.33% | 130.00% | -100.00% | 172.60% | -133.33% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -104.42% | -1,089.80% | 111.36% | 49.83% | 91.13% |